SeaStar Medical Q1 revenue $0.5M, up 69% YoY; net loss $3.5M

SeaStar Medical Holding Corp

Net revenue of $0.5M from QUELIMMUNE sales, vs $0.3M in Q1 2025.
Net loss $3.5M ($0.90/share) vs $3.8M ($4.38/share) a year ago.
Cash $9.3M at March 31, down from $12.0M at Dec 31, 2025.
NEUTRALIZE-AKI trial enrolled 198 of 339 patients; PMA submission efforts initiated.
Added 7 children’s hospitals, now 17 total, targeting 15 more in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.